Standardized treatment of mid-low rectal cancer.
- Author:
Kai-xiong TAO
1
;
Xiao-ming SHUAI
Author Information
1. Department of Gastrointestinal Minimally Invasive Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. tao_kaixiong@163.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Neoadjuvant Therapy;
Neoplasm Staging;
Rectal Neoplasms;
surgery
- From:
Chinese Journal of Gastrointestinal Surgery
2013;16(6):518-520
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the treatment strategy of mid-low rectal cancer has changed from surgical resection alone to multidisciplinary treatment. In order to offer the greatest benefits to the mid-low rectal cancer patients, it is necessary to carry out the preoperative TNM staging for appropriate therapeutic strategies. Total mesorectal excision (TME), preoperative TNM staging and neoadjuvant chemoradiotherapy together may achieve a breakthrough in the therapeutic outcome of mid-low rectal cancer.
